SCHEMBL23926386

SCHEMBL23926386

Cc1ccc(OCc2ccccc2)c(C(O)C2CCCN2C(=O)c2cccc(F)c2O)n1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 1/20 0.37
HCRTR2 O43614 5/20 0.36
NPC1 O15118 1/20 0.35
MAPT P10636 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SPHK2 Q9NRA0 2/20 0.35
PREP P48147 1/20 0.35
HCRTR1 O43613 4/20 0.35
GYS1 P13807 2/20 0.35
SPHK1 Q9NYA1 1/20 0.35
CSF1R P07333 1/20 0.34
HTR1A P08908 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30369527 1.00 GHSR (0.37) GHSRHCRTR2NPC1MAPTCYP2C9
SCHEMBL23926358 0.89 PREP (0.37) HCRTR2MAPTCYP2C9CYP2C19SMN1; SMN2
SCHEMBL30369775 0.89 PREP (0.37) HCRTR2MAPTCYP2C9CYP2C19SMN1; SMN2
SCHEMBL30369520 0.86 MAPT (0.34) HCRTR2MAPTCYP2C9CYP2C19SMN1; SMN2
SCHEMBL23926348 0.86 MAPT (0.34) HCRTR2MAPTCYP2C9CYP2C19SMN1; SMN2
SCHEMBL23926345 0.84 PREP (0.41) HCRTR2NPC1L3MBTL1SPHK2PREP
SCHEMBL30118961 0.82 SPHK2 (0.41) HCRTR2SPHK2HCRTR1GYS1SPHK1
SCHEMBL23926327 0.82 SPHK2 (0.41) HCRTR2SPHK2HCRTR1GYS1SPHK1
SCHEMBL23926371 0.81 APP (0.40) PREP
SCHEMBL23964440 0.80 KLK7 (0.47) GHSRMAPTL3MBTL1PREP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021253091-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2021-12-23 WO disclosed
US-11155547-B1 Compounds for and methods of treating diseases Alterity Therapeutics Limited (AU) 2021-10-26 US disclosed
US-11155547-B1 Compounds for and methods of treating diseases Alterity Therapeutics Limited (AU) 2021-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11155547-B1 Compounds for and methods of treating diseases HTT, SNCA, PARK7 GHSR 1926/4885HCRTR2 711/4885NPC1 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.